natgillin/translations-raw huggingface dataset:
A pharmacokinetic trial in subjects with hepatic impairment has not been conducted.
Farmakokinetičnega preizkušanja pri osebah z okvaro jeter niso izvedli.
A pharmacokinetic/pharmacodynamic analysis suggested a relationship between crizotinib plasma concentration and QTc.
Analiza razmerja farmakokinetika/farmakodinamika je nakazovala povezavo med plazemsko koncentracijo krizotiniba in intervalom QTc.
A Phase 1 interaction study evaluated the effect of cigarette smoking (CYP1A2 inducer) on the pharmacokinetics of Esbriet.
Študija faze I medsebojnega delovanja je ovrednotila učinek kajenja cigaret (induktorja CYP1A2) na farmakokinetiko zdravila Esbriet.
A phase 2 study of pemetrexed in 31 solid tumour patients with stable third space fluid demonstrated no difference in pemetrexed dose normalized plasma concentrations or clearance compared to patients without third space fluid collections.
V študiji s pemetreksedom so v fazi II pri 31 bolnikih s solidnim tumorjem in stabilno tekočino tretjega prostora pokazali, da ni razlike med normalno koncentracijo v plazmi ali očistkom, doseženo glede na odmerek pemetrekseda, v primerjavi z bolniki brez zaloge tekočine tretjega prostora.
A phase 2 study of sunitinib was conducted in patients who were refractory to prior cytokine therapy with interleukin-2 or IFN-.
Pri bolnikih, odpornih proti prejšnjemu citokinskemu zdravljenju z interlevkinom-2 ali IFN-, so opravili študijo 2. faze s sunitinibom.
a Phase 3 dose optimisation study results reported at 2 year study follow up. b CA180-034 study results in recommended starting dose of 100 mg once daily. c CA180-035 study results in recommended starting dose of 140 mg once daily.
a Rezultati študije 3. faze za določitev optimalnega odmerka po 2-letnem obdobju spremljanja. b Rezultati študije CA180-034 pri uporabi priporočenega začetnega odmerka 100 mg enkrat na dan. c Rezultati študije CA180-035 pri uporabi priporočenega začetnega odmerka 140 mg enkrat na dan.
a Phase 3 dose optimisation study results reported at the recommended starting dose of 140 mg once daily (n=304) population at 2 year final study follow up. b Includes ventricular dysfunction, cardiac failure, cardiac failure congestive, cardiomyopathy, congestive cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and ventricular failure.
a Rezultati študije 3. faze za določitev optimalnega odmerka pri uporabi priporočenega začetnega odmerka 140 mg enkrat na dan (n=304) po končanem 2-letnem obdobju spremljanja. b Vključuje ventrikularno disfunkcijo, srčno popuščanje, kongestivno srčno popuščanje, kardiomiopatijo, kongestivno kardiomiopatijo, diastolno disfunkcijo, zmanjšanje iztisnega deleža in ventrikularno popuščanje.
A phase 3, randomized, double-blind, placebo-controlled study of sunitinib was conducted in patients with GIST who were intolerant to, or had experienced disease progression during or following treatment with, imatinib (median maximum daily dose 800 mg).
Pri bolnikih z GIST, ki so bili odporni proti imatinibu ali jim je bolezen med zdravljenjem ali po zdravljenju z njim napredovala (mediana največjega dnevnega odmerka 800 mg), so opravili randomizirano, dvojno slepo, s placebom nadzorovano študijo 3. faze s sunitinibom.
A phase 3, randomized, multi-centre international study evaluating the efficacy and safety of sunitinib compared with IFN- in treatment-naïve MRCC patients was conducted.
Pri bolnikih s še nezdravljenim MRCC so opravili randomizirano, multicentrično mednarodno študijo 3. faze za oceno učinkovitosti in varnosti sunitiniba v primerjavi z interferonom IFN-.
A Phase 4 study was conducted to assess safety, efficacy, and pharmacokinetics of daptomycin in paediatric patients (1 to 17 years old, inclusive) with cSSTI caused by Gram-positive pathogens.
Z oceno varnosti, učinkovitosti in farmakokinetike daptomicina pri pediatričnih bolnikih, ki so stari od 1 do vključno 17 let in imajo zapletene okužbe kože in mehkih tkiv, katerih povzročitelji so po Gramu pozitivne bakterije, so izvedli študijo faze 4.
A phase I dose-escalation study of oral sunitinib was conducted in 35 paediatric and young adult patients (aged 2-21) with refractory solid tumours, the majority of whom had a primary diagnosis of brain tumour.
Študija s povečevanjem odmerka peroralnega sunitiniba 1. faze je potekala pri 35 pediatričnih in mlajših odraslih bolnikih (starih 2-21 let) z neodzivnimi čvrstimi tumorji, med katerimi je imela večina primarno diagnozo možganskega tumorja.
A phase I dose-escalation study of oral sunitinib was conducted in paediatric and young adult patients (aged 2-21) with refractory solid tumours, the majority of whom were enrolled with a primary diagnosis of brain tumour.
Študija s povečevanjem odmerka peroralnega sunitiniba 1. faze je potekala pri pediatričnih in mlajših odraslih bolnikih (starih 2-21 let) z neodzivnimi čvrstimi tumorji, med katerimi je imela večina ob vključitvi v študijo primarno diagnozo možganskega tumorja.
A phase I study in 18 obese patients with type 2 diabetes mellitus (BMI between 35 and 40 kg/m2) with insulin glulisine and insulin lispro [90% CI: 0.81, 0.95 (p=<0.01)] has shown that insulin glulisine effectively controls diurnal postprandial blood glucose excursions.
Študija faze I, izvedena pri 18 bolnikih s prekomerno telesno maso in diabetesom mellitusom tipa 2 (indeks telesne mase med 35 in 40 kg/m2) z insulinom glulisin in insulinom lispro [90 % interval zaupanja: 0,81; 0,95 (p = < 0,01)] je pokazala, da insulin glulisin učinkovito nadzira dnevno post- prandialno nihanje glukoze v krvi.
A phase I study in patients with type 1 diabetes mellitus assessed the glucose lowering profiles of insulin glulisine and regular human insulin administered subcutaneously at a dose of 0.15 Units/kg, at different times in relation to a 15-minute standard meal.
Študija faze I pri bolnikih z diabetesom mellitusom tipa 1 je ocenjevala znižanje glukoze z insulinom glulisin in navadnim humanim insulinom, apliciranima subkutano v odmerku 0,15 enot/kg ob različnih časih glede na 15-minutni standardni obrok.
A Phase I study was conducted to evaluate the PK of the components of Teysuno and their metabolites in cancer patients with impaired renal function compared to those with normal renal function.
Pri bolnikih z rakom in poslabšanim delovanjem ledvic so opravili študijo 1. faze za ocenjevanje farmakokinetike sestavin zdravila Teysuno in njihovih presnovkov v primerjavi z bolniki z rakom in normalnim delovanjem ledvic.
A phase II study examined dabigatran etexilate and warfarin in a total of 252 patients with recent mechanical valve replacement surgery (i.e. within the current hospital stay) and in patients who received a mechanical heart valve replacement more than three months ago.
V raziskavi II. faze so dabigatran eteksilat in varfarin preverili pri skupno 252 bolnikih z nedavno operativno vstavitvijo umetne srčne zaklopke (med bivanjem v bolnišnici) in pri bolnikih, ki so jim umetno srčno zaklopko vstavili pred več kot tremi meseci.
A phase II study examined dabigatran etexilate and warfarin in a total of 252 patients with recent mechanical valve replacement surgery (i.e. within the current hospital stay) and in patients who received a mechanical heart valve replacement more than three months ago.
V raziskavi II. faze so dabigatran eteksilat in varfarin preverili pri skupno 252 bolnikih z nedavno operativno vstavitvijo umetne zaklopke (med bivanjem v bolnišnici) in pri bolnikih, ki so jim umetno srčno zaklopko vstavili pred več kot tremi meseci.
A phase II, randomised double-blind study of two dose levels (200 mg or 800 mg once daily) of Odomzo was conducted in 230 patients with either locally advanced basal cell carcinoma (laBCC) (n=194) or metastatic basal cell carcinoma (mBCC) (n=36).
Študijo faze II, ki je bila randomizirana, dvojno slepa študija z dvema višinama odmerka zdravila Odomzo (200 mg oziroma 800 mg enkrat na dan), so izvajali pri 230 bolnikih, ki so imeli bodisi lokalno napredovali bazalnocelični karcinom (n=194) ali metastatski bazalnocelični karcinom (n=36).
A Phase II, single arm activity, safety, and pharmacokinetic trial conducted by the Children’s Oncology Group assessed the activity of the addition of bortezomib to multi agent re induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]).
V farmakokinetični študiji varnosti in učinkovitosti faze II, z enim krakom, ki jo je izvedla Skupina za otroško onkologijo (COG – Children’s Oncology Group), so ocenili delovanje bortezomiba, ki so ga dodali k ponovno uvedeni indukcijski kemoterapiji z več zdravili pri pediatričnih in mladih odraslih bolnikih z limfatičnimi malignomi (s pre-B-celično akutno limfoblastno levkemijo [ALL], T-celično ALL in T-celičnim limfoblastnim limfomom [LL]).
A Phase II, single arm activity, safety, and pharmacokinetic trial conducted by the Children’s Oncology Group assessed the activity of the addition of bortezomib to multi agent re induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]).
V farmakokinetični študiji varnosti in učinkovitosti faze II, z enim krakom, ki jo je izvedla Skupina za otroško onkologijo (COG- Children’s Oncology Group) so ocenili delovanje bortezomiba, ki so Ga dodali k ponovno uvedeni indukcijski kemoterapiji z več zdravili pri pediatričnih in mladih odraslih bolnikih z limfatičnimi malignomi (s pre-B-celično akutno limfoblastno levkemijo [ALL], T-celično ALL in T-celičnim limfoblastnim limfomom [LL]).
A Phase II, single-arm activity, safety, and pharmacokinetic trial conducted by the Children’s Oncology Group assessed the activity of the addition of bortezomib to multi-agent re-induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]).
V farmakokinetični študiji varnosti in učinkovitosti faze II, z enim krakom, ki jo je izvedla Skupina za otroško onkologijo (COG- Children’s Oncology Group) so ocenili delovanje bortezomiba, ki so ga dodali k ponovno uvedeni indukcijski kemoterapiji z več zdravili pri pediatričnih in mladih odraslih bolnikih z limfatičnimi malignomi (s pre-B-celično akutno limfoblastno levkemijo [ALL], T-celično ALL in T-celičnim limfoblastnim limfomom [LL]).
A Phase II, single-arm, open-label study evaluated the effects of trastuzumab emtansine in patients with HER2-positive incurable, LABC or MBC.
To je bila odprta študija faze II z eno skupino, ki je ocenila učinke trastuzumaba emtanzina pri bolnikih s HER2-pozitivnim, neozdravljivim lokalno napredovalim ali metastatskim rakom dojk.
A phase III clinical trial was completed in 736 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.
Opravljeno je bilo klinično preskušanje III. faze pri 736 ženskah po menopavzi z napredovalim rakom dojke, ki se jim je bolezen ponovila med ali po adjuvantnem endokrinološkem zdravljenju, ali je napredovala po endokrinološkem zdravljenju napredovale bolezni.
A Phase III international, multicentre, open label, randomised, two-stage, three-arm clinical study (BO21004/CLL11) investigating the efficacy and safety of Gazyvaro plus chlorambucil (GClb) compared to rituximab plus chlorambucil (RClb) or chlorambucil (Clb) alone was conducted in patients with previously untreated chronic lymphocytic leukaemia with comorbidities.
Mednarodna, multicentrična, odprta, randomizirana, dvostopenjska klinična študija faze III s tremi skupinami (BO21004/CLL11) za preučitev učinkovitosti in varnosti kombinacije zdravila Gazyvaro in klorambucila (GClb) v primerjavi s kombinacijo rituksimaba in klorambucila (RClb) ter s klorambucilom (ClB) je bil izvedena pri bolnikih s še nezdravljeno kronično limfocitno levkemijo in komorbidnimi stanji.
A phase III multicentre, randomised, blinded study was conducted to assess the safety and efficacy of pasireotide intramuscular use versus octreotide intramuscular use in medically naïve patients with active acromegaly.
Multicentrično, randomizirano, slepo študijo faze III so izvajali za presojo varnosti in učinkovitosti intramuskularne uporabe pasireotida v primerjavi z intramuskularno uporabo oktreotida pri bolnikih z aktivno akromegalijo, ki predhodno še niso bili zdravljeni.
A phase III trial (study 478) compared oral topotecan plus Best Supportive Care (BSC) (n=71) with BSC alone (n=70) in patients who had relapsed following first line therapy (median time to progression [TTP] from first-line therapy: 84 days for oral topotecan + BSC, 90 days for BSC) and for whom retreatment with intravenous chemotherapy was not considered appropriate.
Raziskava je bila opravljena pri bolnikih, pri katerih je po zdravljenju s terapijo prve izbire prišlo do relapsa (srednji čas do progresije, ki je minil od zdravljenja s terapijo prve izbire: 84 dni za zdravljenje s peroralnim topotekanom v kombinaciji z NPO; 90 dni za zdravljenje z NPO samo) in pri katerih zdravljenje z intravensko obliko kemoterapije ni bilo primerno.
A phase III trial (study 478) compared oral topotecan plus Best Supportive Care (BSC) (n=71) with BSC alone (n=70) in patients who had relapsed following first line therapy (median time to progression [TTP] from first-line therapy: 84 days for oral topotecan + BSC, 90 days for BSC) and for whom retreatment with intravenous chemotherapy was not considered appropriate.
V preskušanju III. faze (študija 478) so primerjali peroralni topotekan v kombinaciji z najboljšo podporno oskrbo (NPO) (n = 71) in NPO samo (n = 70) pri bolnikih z relapsom po terapiji prve izbire (mediani čas do napredovanja od terapije prve izbire: 84 dni za peroralni topotekan in NPO, 90 dni za NPO), pri katerih ponovno zdravljenje z intravensko kemoterapijo ni bilo primerno.
A phase III trial (study 478) compared oral topotecan plus Best Supportive Care (BSC) (n=71) with BSC alone (n=70) in patients who had relapsed following first line therapy (median time to progression [TTP] from first-line therapy: 84 days for oral topotecan + BSC, 90 days for BSC) and for whom retreatment with intravenous chemotherapy was not considered appropriate.
V preskušanju III. faze (študija 478) so primerjali uporabo peroralnega topotekana skupaj z najboljšo podporno oskrbo (NPO) (n = 71) s samo NPO (n = 70) pri bolnikih, ki so imeli ponovitev bolezni po zdravljenju s terapijo prve izbire (mediana vrednost časa do napredovanja bolezni [TTP], ki je minil od zdravljenja s terapijo prve izbire: 84 dni za peroralni topotekan v kombinaciji z NPO in 90 dni za samo NPO) in pri katerih ponovno zdravljenje z intravensko kemoterapijo ni bilo primerno.
A phase III, multicentre, randomised study was conducted to evaluate the safety and efficacy of different dose levels of Signifor over a twelve-month treatment period in Cushing’s disease patients with persistent or recurrent disease or de novo patients for whom surgery was not indicated or who refused surgery.
Pri bolnikih s Cushingovo boleznijo, ki so imeli persistentno ali rekurentno obliko bolezni oziroma so jim bolezen šele odkrili in niso bili primerni za kirurški poseg ali pa so ga odklonili, so izvedli multicentrično, randomizirano študijo faze III za oceno varnosti in učinkovitosti različnih odmerkov zdravila Signifor v 12-mesečnem obdobju zdravljenja.
A PhotoBarr 15 mg vial will be needed for every additional 7.5 kg body weight.
15 mg-viala PhotoBarra se doda na vsakih dodatnih 7,5 kg telesne mase.
A picture, known as a scan, can be taken.
Posnamemo lahko sliko.
a piece of gauze bandage or a sterile gauze swab, a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.
alkoholni čistilni robček, košček povoja iz gaze ali sterilno vatno blazinico.
a piece of gauze bandage or a sterile gauze swab, a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.
kos gaze ali sterilnega zloženca, vsebnik, odporen na vbode (plastični vsebnik, ki ga dobite v bolnišnici ali lekarni), da lahko varno zavržete uporabljene injekcijske brizge.
a piece of gauze bandage or a sterile gauze swab, a puncture-proof container (plastic container provided by the hospital or pharmacy) so you can dispose of used syringes safely.
košček povoja iz gaze ali sterilno vatno blazinico, vsebnik, odporen proti vbodom (plastični vsebnik, ki ga dobite v bolnišnici ali lekarni), da lahko varno zavržete uporabljene brizge.
A pilot dose-finding and pharmacokinetic study of fondaparinux in children with deep vein thrombosis
Pilotska študija določitve odmerka in farmakokinetike fondaparinuksa pri otrocih z globoko vensko trombozo
A pilot study was conducted for newly diagnosed patients from 1 to 30 years of age with high risk
Opravljena je bila pilotna študija pri bolnikih, starih od 1 do 30 let, z novo diagnozo ALL
A pink, biconvex, oval tablet, with the inscription “OL 20” on one side.
Roza, bikonveksna ovalna tableta z napisom »OL 20« na eni strani.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3-14) included a total of 252 outpatients.
V temeljni klinični študiji pri skupini 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo (3–14 točk na lestvici Kratkega preskusa spoznavnih sposobnosti (KPSS oz.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
V klinični študiji, ki podpira vlogo za pridobitev dovoljenja za promet pri skupini 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo (3–14 točk na lestvici Kratkega preskusa spoznavnih sposobnosti (KPSS oz.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
V klinični študiji, ki podpira vlogo za pridobitev dovoljenja za promet, pri skupini 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo (3–14 točk na lestvici KPSS ("Kratkem preskusu spoznavnih sposobnosti" oz.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
V temeljni klinični študiji pri skupini 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo (3–14 točk na lestvici Kratkega preskusa spoznavnih sposobnosti (KPSS oz.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
V temeljno klinično študijo je bilo vključenih 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo, ki so ob vključitvi pri kratkem preizkusu spoznavnih sposobnosti (KPSS, angl. mini-mental state examination, MMSE) dosegli 3-14 točk.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer’s disease (mini mental state examination (MMSE) total scores at baseline of 3-14) included a total of 252 outpatients.
V temeljni klinični študiji pri skupini 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo (3–14 točk na lestvici KPSS ("Kratkem preskusu spoznavnih sposobnosti" oz.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer’s disease (MMSE total scores at baseline of 10 to 22) included 403 patients.
Temeljna študija memantina v monoterapiji pri zdravljenju bolnikov z blago do zmerno Alzheimerjevo boleznijo (skupna ocena ob vključitvi 10 do 22 točk na KPSS) je zajela 403 bolnike.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer’s disease (MMSE total scores at baseline of 10 to 22) included 403 patients.
Temeljna študija memantina v monoterapiji pri zdravljenju bolnikov z blago do zmerno Alzheimerjevo boleznijo (skupna ocena pri KPSS ob vključitvi 10 do 22 točk) je zajela 403 bolnike.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer’s disease (MMSE total scores at baseline of 10 to 22) included 403 patients.
Temeljna študija memantina v monoterapiji pri zdravljenju bolnikov z blago do zmerno Alzheimerjevo boleznijo (skupna ocena pri KPSS ob vključitvi od 10 do 22 točk) je zajela 403 bolnike.
A pivotal phase 3, multi-centre, international, randomized, double-blind placebo-controlled study of single-agent sunitinib was conducted in patients with unresectable pNET.
Pri bolnikih z neizrezljivim pNET so opravili ključno, multicentrično, mednarodno, randomizirano, dvojno slepo, s placebom nadzorovano študijo 3. faze.
A place to prepare your supplies:
Prostor za pripravo vseh potrebnih stvari:
a Placebo-controlled clinical studies (phase III) in moderate to severe plaque psoriasis patients exposed to ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W or placebo for up to 12 weeks of treatment duration b Upper respiratory tract infection includes nasopharyngitis and upper respiratory tract infection c Oral candidiasis defined as events with the preferred terms oral candidiasis and oral fungal infection d Cellulitis includes staphylococcal and external ear cellulitis, and erysipelas e Injection site reactions were more common in subjects with a body weight < 60 kg compared with the group with a body weight ≥ 60 kg (25 % vs.
a S placebom nadzorovane klinične študije (3. faze) pri bolnikih z zmerno do hudo psoriazo s plaki, ki so bili izpostavljeni iksekizumabu 80 mg Q2W, iksekizumabu 80 mg Q4W ali placebu do 12 tednov v obdobju zdravljenja. b Okužbe zgornjih dihalnih poti vključujejo nazofaringitis in okužbo zgornjih dihalnih poti. c Oralna kandidaza je definirana kot dogodki s priporočenima izrazoma oralna kandidaza in oralna glivična okužba. d Celulitis vključuje stafilokokni celulitis in celulitis zunanjega ušesa ter erizipel. e Reakcije na mestu injiciranja so bile bolj pogoste pri bolnikih s telesno maso < 60 kg, v primerjavi s skupino, ki je imela telesno maso ≥ 60 kg (25 % v primerjavi s 14 % za kombinirani skupini Q2W in
A placebo-controlled study of 24 weeks in duration was conducted to evaluate the efficacy and safety of linagliptin 5 mg to placebo, in patients not sufficiently treated with a combination with metformin and a sulphonylurea.
Učinkovitost in varnost linagliptina po 5 mg v primerjavi s placebom so ocenili v s placebom nadzorovani 24-tedenski študiji pri bolnikih z nezadostno urejeno boleznijo ob zdravljenju s kombinacijo metformina in sulfonilsečnine.
A placebo-controlled study of 24 weeks in duration was conducted to evaluate the efficacy and safety of linagliptin 5 mg to placebo, in patients not sufficiently treated with a combination with metformin and a sulphonylurea.
V s placebom nadzorovani 24-tedenski študiji so ocenjevali učinkovitost in varnost linagliptina v odmerkih po 5 mg v primerjavi s placebom pri bolnikih, pri katerih kombinacija metformina in sulfonilsečnine ni bila dovolj učinkovita.
A placebo-controlled study of 24-week duration was conducted to evaluate the efficacy and safety of saxagliptin in combination with a thiazolidinedione (TZD) in patients with inadequate glycaemic control (HbA1c 7-10.5%) on TZD alone.
Narejena je bila 24-tedenska s placebom kontrolirana študija za oceno učinkovitosti in varnosti saksagliptina v kombinaciji s tiazolidindionom pri bolnikih, ki med monoterapijo s tiazolidindionom niso imeli ustrezno urejene glikemije (HbA1c od 7 % do 10,5 %).